title: Overexpression of the peripheral benzodiazepine receptor is a relevant prognostic factor in stage III colorectal cancer.
abstract: OBJECTIVE
  The peripheral benzodiazepine receptor (PBR) has been implicated in the growth control of colorectal cancer, where PBR-specific ligand-binding is increased 3-4-fold. However, the prognostic relevance of PBR (over) expression has not yet been evaluated in colorectal cancer.
  
  
  METHODS
  A 5-year follow-up was performed in 116 consecutive patients undergoing surgery for colorectal cancer with regional or distant metastases [Union International Contre le Cancer (UICC) stage III, 59 patients; UICC stage IV, 57 patients]. The monoclonal anti-PBR antibody 8 D7 was used for immunohistochemical examination of paraffin-embedded sections. PBR-specific staining was compared in cancer tissues and normal mucosa. Kaplan-Meier survival curves were calculated.
  
  
  RESULTS
  Twenty-eight % of the colorectal cancers strongly overexpressed PBR. The mean survival of patients with stage III cancer was 56.2 +/- 9.2 months with and 86.8 +/- 6.6 months without high overexpression of PBR (P = 0.006). Univariate and multivariate analyses revealed that high PBR overexpression is an independent unfavorable prognostic factor in stage III colorectal cancer. In stage IV, however, the PBR status did not correlate with different survival times.
  
  
  CONCLUSIONS
  Strong PBR overexpression is a new independent prognostic marker in stage III colorectal cancer. Evaluating PBR overexpression may be useful for stratifying risk and developing risk-adapted strategies of adjuvant therapy.
authors.affiliation: Medical Clinic I and Department of Surgery, University Hospital Benjamin Franklin, Free University of Berlin, 12200 Berlin, Germany.
authors.forename: Kerstin
authors.initials: K
authors.lastname: Maaser
authors.forename: Patricia
authors.initials: P
authors.lastname: Grabowski
authors.forename: Andreas P
authors.initials: AP
authors.lastname: Sutter
authors.forename: Michael
authors.initials: M
authors.lastname: Höpfner
authors.forename: Hans-Dieter
authors.initials: HD
authors.lastname: Foss
authors.forename: Harald
authors.initials: H
authors.lastname: Stein
authors.forename: Gerd
authors.initials: G
authors.lastname: Berger
authors.forename: Moshe
authors.initials: M
authors.lastname: Gavish
authors.forename: Martin
authors.initials: M
authors.lastname: Zeitz
authors.forename: Hans
authors.initials: H
authors.lastname: Scherübl
mesh_terms: D000230:Adenocarcinoma / Q000378:metabolism* / Q000556:secondary / Q000601:surgery; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D016022:Case-Control Studies; D015179:Colorectal Neoplasms / Q000378:metabolism* / Q000473:pathology / Q000601:surgery; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007124:Immunoenzyme Techniques; D007413:Intestinal Mucosa / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D011963:Receptors, GABA-A / Q000378:metabolism*; D015996:Survival Rate
chemical_list: D011963:Receptors, GABA-A